Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (Lundbeck) to market and distribute its own version of Vortioxetine in India under the brand name, ‘Vortidif’. The territory of the licensing agreement will only cover India.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
